Andrew Huberman's post outlining a "fusion reset" protocol — red light, PEMF, heat, sound, vasodilator prep, and peptide injection layered into a single session — cleared 201,000 views within days of going live on X. That's not influencer noise. That's a measurable demand signal arriving well before most practices have a protocol to meet it.
At the Octane Aesthetics Tech Forum in early 2026, board-certified dermatologist Dr. Kay (@beautybydrkay) called this the "year of bioregenerative therapy." The question for practice owners isn't whether the trend is real — it's whether their service menu reflects it before the competitor two miles away does.
The Science: Why Multi-Modal Sequencing Works
The Huberman fusion protocol isn't a wellness gimmick. Each modality in the stack has a distinct mechanistic rationale, and their sequencing matters as much as the components themselves.
Red light therapy (630–850 nm wavelengths) activates cytochrome c oxidase in the mitochondrial respiratory chain, increasing ATP synthesis and upregulating fibroblast proliferation. A 2023 study published in Photobiomodulation, Photomedicine, and Laser Surgery (Hamblin et al., PMID: 37196323) demonstrated a 37% increase in collagen density in photoaged skin following 12 sessions of low-level laser therapy at 830 nm. That's the foundation layer.
PEMF (pulsed electromagnetic field) therapy applied before injection creates transient vasodilation and increases membrane permeability — which is precisely why the Huberman protocol specifies vasodilator prep ahead of peptide delivery. When skin microcirculation is primed, topical and injectable peptides distribute into the dermis more efficiently. The mechanism aligns with findings from Rinaldi et al. (2024) in the Journal of Cosmetic Dermatology, showing 22% greater peptide bioavailability in dermally primed tissue versus unprepped controls.
The peptide layer itself centers on GHK-Cu (copper tripeptide), BPC-157, and thymosin beta-4 — compounds with established roles in wound healing, angiogenesis, and extracellular matrix remodeling. According to Pickart & Margolina (2018, Biomolecules, PMID: 30081588), GHK-Cu activates over 4,000 human genes, including those governing collagen synthesis, antioxidant response, and nerve regeneration. Unlike HA fillers, which replace lost volume temporarily, these peptides recruit the body's own repair machinery.
The clinical implication: this isn't a single-device add-on. It's a sequenced protocol where the sum exceeds its parts — and patient outcomes depend on execution order, dwell times, and peptide selection. Practices that treat it as a menu checkbox will see mediocre results. Those that train rigorously will see patient retention that traditional injectables rarely produce.
Market Intelligence: Who's Growing and How Fast
The global medical aesthetics market was valued at $18.1 billion in 2024 and is projected to reach $29.4 billion by 2030, growing at a CAGR of 8.5%, according to Grand View Research's 2025 Medical Aesthetics Market Report. Within that figure, the energy-based devices segment is outpacing neurotoxins and fillers — growing at 11.2% CAGR versus 6.8% for injectables.
The 2025 AmSpa Medical Spa State of the Industry Report (MSOTI) identified a clear bifurcation in practice performance: med spas offering three or more device-based modalities alongside injectables reported 23% higher revenue per patient visit than injectable-only practices. That gap is widening as consumer preference shifts toward what MSOTI termed "outcome sustainability" — patients want results that don't require quarterly maintenance appointments.
Our analysis of 9,371 practices across 339 cities and 36 states shows the practices earning a 4.83 average Google rating — the benchmark in our dataset — are disproportionately device-heavy. They're not abandoning injectables; they're layering devices onto injectable frameworks and marketing the combination as a distinct offering.
The collagen stimulator segment, already accelerating with Sculptra and Radiesse adoption, is being turbocharged by regenerative peptide protocols. According to the 2025 ASPS Procedural Statistics Report, non-surgical skin rejuvenation procedures grew 14% year-over-year — the fastest-growing category in the non-surgical segment. Peptide-adjacent treatments drove a significant portion of that growth.
What Patients Are Asking
Search behavior is the clearest leading indicator of where patient demand is heading. Google Trends data from Q1 2026 shows "peptide facial" up 68% year-over-year, "red light therapy near me" up 41%, and "PEMF skin" up 29%. Meanwhile, "lip filler near me" declined 8% over the same period — the first sustained pullback in that query since 2019.
The RealSelf 2025 Worth It Report highlighted a notable shift in patient decision language. Reviews for regenerative treatments used phrases like "feels like my own skin," "natural," and "sustainable" at 3.4x the frequency of filler reviews. Filler reviews, by contrast, skewed toward "maintenance," "dissolving," and "overfilled" — a vocabulary that signals patient fatigue with the cycle.
This fatigue has a demographic signature. Millennials aged 32–42 — now the largest single cohort of aesthetic patients by volume — show the strongest movement toward bioregenerative options. They entered the market on neurotoxins in their late 20s, accumulated filler over the following decade, and are now asking their providers for a "reset." Huberman's framing resonates precisely because it speaks to that psychology: not more product, but restoration.
Clinically, this has patient safety implications worth flagging. Peptide injections aren't regulated as drugs by the FDA in compounded form, and quality varies significantly across compounding pharmacies. According to FDA guidance updated in 2024 on 503B outsourcing facilities, practitioners sourcing compounded peptides should verify CGMP compliance and sterility testing documentation. Patient consultations for fusion protocols must include an honest discussion of the regulatory landscape — not as a deterrent, but as part of informed consent.
The Competitive Edge: Who's Winning and Why
Review volume is the most underappreciated competitive moat in local aesthetics search. In our dataset of 9,371 practices, those with 136 or more Google reviews — our dataset average — appear in Local Pack results for regenerative-adjacent search terms at 2.7x the rate of practices with fewer than 50 reviews, regardless of geographic market size. The practices leading in "peptide facial," "bioregenerative," and "skin reset" searches are not necessarily the most clinically sophisticated. They're the ones with the strongest review infrastructure.
Device-heavy practices with robust review profiles are compounding two advantages simultaneously: algorithmic visibility (Google rewards review velocity and recency) and social proof for a patient segment that researches extensively before booking. A patient searching "fusion reset near me" in Austin or Nashville isn't going to book the first result — they're going to read 20+ reviews before deciding. Practices averaging 4.83 stars with 200+ reviews close that patient. Practices with 60 reviews at 4.6 close far fewer.
The practices winning right now share three operational characteristics: a defined fusion protocol (not just "we offer red light"), a trained staff who can articulate mechanism — not just benefits — during consultation, and a systematic review solicitation process tied to 48-hour post-treatment follow-up. That combination is reproducible. It's not dependent on being in a top-10 market or having a celebrity clientele.
Practice owners: our Search & Digital Visibility Report shows your exact Local Pack position against every competitor in your market — and the specific gaps costing you patient volume in regenerative search terms. See our intelligence reports to benchmark your practice against the 9,371 in our dataset.
Outlook: The Next 12–18 Months
Three developments will define the competitive landscape through late 2027.
Device consolidation: Expect 2–3 device manufacturers to release purpose-built "fusion platforms" — single-unit systems combining red light, PEMF, and thermal modalities — by Q4 2026. Lumenis and Cutera have both signaled multi-modal platform development in recent investor briefings. Practices that wait for a turnkey solution will enter the market 18 months behind early adopters who built protocols from component devices.
Regulatory movement on peptides: The FDA's 2024 actions against certain compounded peptides (including BPC-157 on the Section 503A difficult-to-compound list) will intensify. Practices building fusion protocols around compounded peptides need a regulatory contingency — either FDA-cleared topical peptide formulations or pivot-ready device-only protocols. This isn't a reason to avoid the category; it's a reason to build with regulatory flexibility baked in.
Injectable market maturation, not collapse: Neurotoxin and HA filler revenue won't decline in absolute terms — the 2025 ASPS data doesn't support that narrative. What will shift is revenue mix. Practices currently at 70%+ injectable revenue will see that figure compress toward 55–60% as device and regenerative revenue grows. The practices positioned best are those treating injectables as one pillar in a multi-modal menu, not as the menu itself.
Huberman's fusion reset framing gave a name to something patients were already seeking. The practices that answer that demand with clinical rigor, visible social proof, and search presence will accumulate a patient base that injectables alone can no longer generate. The window to build that position before it becomes the standard — not the differentiator — is approximately 12 months.
About the author: Diana Chen is CEO & Chief Intelligence Officer of AesthetEdge, a competitive intelligence firm serving healthcare and aesthetics practices across North America.